Dr. Abbey Discusses Retinal Vein Occlusion as a Marker of Systemic Risk
Texas Retina’s Ashkan Abbey, MD, recently appeared on the ReachMD podcast to discuss “Retinal Vein Occlusion as a Marker of Systemic Risk.” This was the third episode he contributed to their “Eye
read more
Honoring Our Physicians
In recognition of National Doctors’ Day, Texas Retina honors and celebrates our wonderful physicians and all the doctors who care for patients throughout the communities we serve. Thank you for your daily
read more Dr. Abbey Discusses Retinal Vein Occlusion on ReachMD Podcast
Texas Retina’s Ashkan Abbey, MD, recently appeared on the ReachMD podcast as part of their “Spotlight on Retinal Vein Occlusion” series. In the first episode of this series, Dr. Abbey discusses distinguishing urgent
read more Dr. Abbey Publishes Case Report on New Approach to Treating Chronic Postoperative Cystoid Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently collaborated with colleagues from the Department of Ophthalmology at University of Texas Southwestern Medical Center in Dallas, to publish a case report in Retinal Cases &
read more
What to Expect at Your Retina Exam
Retina exams are typically more involved than a routine eye exam. At Texas Retina, we make every effort to evaluate, test, diagnose and treat you all on the same day. As a
read more
Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more
Dr. Ashkan Abbey Presented at the American Academy of Ophthalmology Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented, taught and served as a panelist at AAO 2025, the American Academy of Ophthalmology’s annual meeting held in Orlando, Florida, October 18-20, 2025. Highlights of
read more Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD
On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic
read more